DDAVP in the treatment of central diabetes insipidus.
DDAVP in the treatment of central diabetes insipidus.
复制标题
DDAVP治疗中枢性尿崩症。
DOI：
10.1056/nejm197603042941001
复制
发表时间：
1976
期刊：
影响因子：
--
通讯作者：
A. G. Robinson
中科院分区：
文献类型：
--
作者：
A. G. Robinson
DDAVP，1-脱氨基-8-d-精氨酸加压素，是加压素的合成类似物，具有增加的抗利尿活性和降低的升压活性。而精氨酸加压素的抗利尿剂与升压剂的比值为1，DDAVP的抗利尿剂与升压剂的比值为4000。当以鼻内喷雾剂给药时，5 - 20 μ g DDAVP对完全性中枢性尿崩症患者产生8 - 20小时的抗利尿作用。在大多数患者中，最小推荐治疗剂量导致最大抗利尿作用。在临床试验中没有发现这种药物的副作用。因此，DDAVP有望成为严重中枢性尿崩症的标准治疗方法。
DDAVP, 1-desamino-8-d-arginine-vasopressin, is a synthetic analogue of vasopressin with increased antidiuretic activity and decreased pressor activity. Whereas the antidiuretic-to-pressor ratio of arginine vasopressin is 1, the antidiuretic-to-pressor ratio of DDAVP is 4000. When administered as an intranasal spray, 5 to 20 mug of DDAVP produced eight to 20 hours of antidiuresis in patients with complete central diabetes insipidus. The minimum recommended therapeutic dose resulted in a maximum antidiuresis in most patients. No side effects of the drug were noted in clinical trials. DDAVP thus gives promise of becoming the standard treatment of severe central diabetes insipidus.